News VITA 34 AG London S.E.

Equities

0NLV

DE000A0BL849

End-of-day quote London S.E. Other stock markets			5-day change	1st Jan Change
- ^PTS	-.--%		-.--%	-.--%

Jun. 01	VITA 34 AG Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 30	VITA 34 AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

VITA 34 AG Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 31	CI
Vita 34 significantly increases earnings and operating cash flow in the first quarter	May. 31	EQ
Vita 34 returns to growth path in 2023	Apr. 30	EQ
VITA 34 AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 29	CI
VITA 34 : Declaration of Conformity 2024	Apr. 26	PU
AFR: Vita 34 AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	Apr. 25	EQ
Vita 34 closes 2023 with significantly better results than expected based on preliminary figures	Apr. 19	EQ
Vita 34 publishes preliminary figures on the course of business in 2023	Jan. 31	EQ
Vita 34 downsizes Management Board until further notice	Jan. 02	EQ
DD: Vita 34 AG: AOC Health GmbH, Acquisition of shares as part of a capital increase	Dec. 11	EQ
DD: Vita 34 AG: Jakub Julian Baran, buy	Dec. 11	EQ
NVR: Vita 34 AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	Dec. 07	EQ
Vita 34 AG: resolves on cash capital increase under exclusion of subscription rights in the amount of up to 10% of the share capital, commitments from investors	Nov. 27	EQ
Vita 34 increases revenue and earnings in Q3 2023 and further stabilizes business development	Nov. 24	EQ
VITA 34 AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 23	CI
AFR: Vita 34 AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements	Nov. 17	EQ
Internal investigation by Vita 34 AG reveals irregularities related to a limited number of biological samples at one of its subsidiaries regarding compliance with medical law requirements	Nov. 10	EQ
Vita 34 AG: A subsidiary of Vita 34, FamiCordTx, will file a lawsuit against a US licensor	23-09-27	EQ
VITA 34 AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI
Vita 34 stabilizes business development in the second quarter and noticeably improves earnings	23-08-31	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News VITA 34 AG London S.E.

Equities

0NLV

DE000A0BL849

Summary

Filters